ITUA20162343A1 - INTRANASAL FORMULATIONS OF BDNF FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES - Google Patents

INTRANASAL FORMULATIONS OF BDNF FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

Info

Publication number
ITUA20162343A1
ITUA20162343A1 ITUA2016A002343A ITUA20162343A ITUA20162343A1 IT UA20162343 A1 ITUA20162343 A1 IT UA20162343A1 IT UA2016A002343 A ITUA2016A002343 A IT UA2016A002343A IT UA20162343 A ITUA20162343 A IT UA20162343A IT UA20162343 A1 ITUA20162343 A1 IT UA20162343A1
Authority
IT
Italy
Prior art keywords
bdnf
treatment
neurodegenerative diseases
intranasal formulations
intranasal
Prior art date
Application number
ITUA2016A002343A
Other languages
Italian (it)
Inventor
Luciano Domenici
Original Assignee
Luciano Domenici
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luciano Domenici filed Critical Luciano Domenici
Priority to ITUA2016A002343A priority Critical patent/ITUA20162343A1/en
Publication of ITUA20162343A1 publication Critical patent/ITUA20162343A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
ITUA2016A002343A 2016-04-06 2016-04-06 INTRANASAL FORMULATIONS OF BDNF FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ITUA20162343A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ITUA2016A002343A ITUA20162343A1 (en) 2016-04-06 2016-04-06 INTRANASAL FORMULATIONS OF BDNF FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUA2016A002343A ITUA20162343A1 (en) 2016-04-06 2016-04-06 INTRANASAL FORMULATIONS OF BDNF FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

Publications (1)

Publication Number Publication Date
ITUA20162343A1 true ITUA20162343A1 (en) 2017-10-06

Family

ID=56551478

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUA2016A002343A ITUA20162343A1 (en) 2016-04-06 2016-04-06 INTRANASAL FORMULATIONS OF BDNF FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

Country Status (1)

Country Link
IT (1) ITUA20162343A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215398A1 (en) * 1989-12-05 2003-11-20 Chiron Corporation Method for administering brain-derived neurotrophic factor to the brain
WO2011058449A2 (en) * 2009-11-16 2011-05-19 Hmfra Hungary Limited Liability Company Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215398A1 (en) * 1989-12-05 2003-11-20 Chiron Corporation Method for administering brain-derived neurotrophic factor to the brain
WO2011058449A2 (en) * 2009-11-16 2011-05-19 Hmfra Hungary Limited Liability Company Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SANDRA R. ALCALÁ-BARRAZA ET AL: "Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS", JOURNAL OF DRUG TARGETING, vol. 18, no. 3, April 2010 (2010-04-01), pages 179 - 190, XP055321545, ISSN: 1061-186X, DOI: 10.3109/10611860903318134 *
SIVA RAM KIRAN VAKA ET AL: "Delivery of Brain-Derived Neurotrophic Factor via Nose-to-Brain Pathway", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 29, no. 2, 31 August 2011 (2011-08-31), pages 441 - 447, XP035005698, ISSN: 1573-904X, DOI: 10.1007/S11095-011-0572-9 *
WILLIAM J CALLAHAN ET AL: "Sodium Chloride Enhances the Storage and Conformational Stability of BDNF and PEG-BDNF", PHARMACEUTICAL RESEARCH, vol. 18, no. 3, 1 March 2001 (2001-03-01), New York, pages 261 - 266, XP055321585, Retrieved from the Internet <URL:http://rd.springer.com/content/pdf/10.1023/A:1011034425896.pdf> [retrieved on 20161122], DOI: 10.1023/A:1011034425896 *

Similar Documents

Publication Publication Date Title
DK3706796T3 (en) Exosomes as RNA therapeutic agents
DK3463465T3 (en) EXOSOMERS INCLUDING THERAPEUTIC POLYPEPTIDES
ES2969758T3 (en) Pharmaceutical compositions for use in the therapy of blepharitis
DK3481846T3 (en) 11-SUBSTITUTED 24-HYDROXYSTEROLS FOR USE IN THE TREATMENT OF NMDA-RELATED CONDITIONS
DK3532067T3 (en) LIPOSOMAL FORMULATION FOR USE IN THE TREATMENT OF CANCER
EP3104706A4 (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
DK3882250T3 (en) TETRAHYDROPYRANYL-AMINO-PYRROLOPYRIMIDINONE FOR USE IN THE TREATMENT OF BTK-MEDIATED DISORDERS
MA46867A (en) PHARMACEUTICAL FORMULATIONS
DK3416631T3 (en) THERAPEUTIC SUBSTANCES FOR NEURODEGENERATIVE DISEASES
GB201603104D0 (en) Therapeutic agents
DK3400072T3 (en) Formulations for the treatment of bladder cancer
ES2970186T3 (en) Pharmaceutical formulations and methods of their use
DK3179007T3 (en) ADJUSTABLE GLASS SKIN CONSTRUCTION
DK3578562T3 (en) L-VALINATAMIDE BENZOXABOROL DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES
DK3408265T3 (en) THERAPEUTIC RELATIONS
ZA201902689B (en) Therapeutic protein
DK3452465T3 (en) SUBSTITUTED 2,4-DIAMINOQUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES
IT201600081379A1 (en) Pharmaceutical composition for use in the treatment of prostatic diseases.
PL3377089T3 (en) Compositions comprising cdnf for use in the intranasal treatment of central nervous system diseases
ITUB20152036A1 (en) SPRAY BOOTH FOR SKIN TREATMENT
SG10201913501RA (en) Liposomal formulations
PT3413870T (en) Igmesine for use in the treatment of neurodegenerative diseases
GB201600376D0 (en) Novel therapeutic agents
ITUA20162343A1 (en) INTRANASAL FORMULATIONS OF BDNF FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
ITUA20163037A1 (en) Formulations for use in the treatment or prevention of urological disorders